Swiss Life Asset Management Ltd Has $4.03 Million Holdings in Royalty Pharma PLC $RPRX

Swiss Life Asset Management Ltd trimmed its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 9.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 114,257 shares of the biopharmaceutical company’s stock after selling 11,785 shares during the period. Swiss Life Asset Management Ltd’s holdings in Royalty Pharma were worth $4,031,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. CWM LLC grew its position in Royalty Pharma by 1.5% during the third quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company’s stock worth $656,000 after buying an additional 281 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Royalty Pharma by 9.6% during the 3rd quarter. GAMMA Investing LLC now owns 3,306 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 289 shares during the period. Merit Financial Group LLC lifted its position in shares of Royalty Pharma by 3.5% during the 3rd quarter. Merit Financial Group LLC now owns 9,149 shares of the biopharmaceutical company’s stock valued at $323,000 after acquiring an additional 306 shares during the period. Larson Financial Group LLC grew its holdings in shares of Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 306 shares in the last quarter. Finally, Wedmont Private Capital grew its holdings in shares of Royalty Pharma by 5.1% during the 3rd quarter. Wedmont Private Capital now owns 6,793 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 331 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

RPRX has been the subject of a number of analyst reports. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Royalty Pharma in a research note on Thursday, February 12th. Leerink Partners set a $45.00 price objective on shares of Royalty Pharma in a research note on Thursday, December 11th. TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a report on Friday, February 27th. Morgan Stanley restated an “overweight” rating and issued a $61.00 target price on shares of Royalty Pharma in a research report on Thursday, February 12th. Finally, Citigroup upped their price target on shares of Royalty Pharma from $48.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $48.67.

Insider Buying and Selling

In other Royalty Pharma news, EVP Marshall Urist sold 20,000 shares of the business’s stock in a transaction on Friday, January 30th. The shares were sold at an average price of $41.09, for a total transaction of $821,800.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Terrance P. Coyne sold 114,954 shares of the company’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $42.84, for a total transaction of $4,924,629.36. Following the transaction, the chief financial officer owned 23,972 shares of the company’s stock, valued at $1,026,960.48. This trade represents a 82.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 517,496 shares of company stock valued at $21,418,283. 18.90% of the stock is owned by corporate insiders.

Royalty Pharma Price Performance

Shares of RPRX stock opened at $45.36 on Monday. The business has a fifty day simple moving average of $43.79 and a 200 day simple moving average of $39.93. The company has a market cap of $26.17 billion, a P/E ratio of 33.60 and a beta of 0.40. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.88. Royalty Pharma PLC has a twelve month low of $29.66 and a twelve month high of $47.86.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.13. The firm had revenue of $621.99 million for the quarter, compared to analysts’ expectations of $839.97 million. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%. On average, sell-side analysts forecast that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Friday, February 20th were given a dividend of $0.235 per share. The ex-dividend date was Friday, February 20th. This represents a $0.94 dividend on an annualized basis and a yield of 2.1%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s dividend payout ratio is currently 69.63%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.